Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease

The American Journal of Cardiology
C P CannonE Braunwald

Abstract

Selective thrombin inhibitors are a new class of antithrombotic drugs that, unlike heparin, can effectively inhibit clot-bound thrombin and escape neutralization by activated platelets. Hirulog is a 20 amino acid hirudin-based synthetic peptide that has shown promise in experimental models of thrombosis. Little information is available about the effects of hirulog in patients with coronary artery disease. Forty-five patients undergoing cardiac catheterization, who were taking aspirin, were randomized to receive either (1) hirulog, 0.05 mg/kg intravenous bolus followed by 0.2 mg/kg/hour intravenous infusion until the end of the catheterization; (2) hirulog, 0.15 mg/kg intravenous bolus followed by 0.6 mg/kg/hour intravenous infusion; or (3) heparin; 5,000 U intravenous bolus. Serial activated partial thromboplastin time (APTT), prothrombin time, activated clotting time and fibrinopeptide A were measured. Hirulog produced a dose-dependent prolongation of all coagulation parameters; the 0.6 mg/kg/hour dose prolonged the APTT to 218 +/- 50% of baseline after 2 minutes and 248 +/- 50% of baseline after 15 minutes. The half-life of the effect on APTT was 40 minutes. The hirulog blood level correlated well with the APTT, prothrombin t...Continue Reading

References

Jul 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·A B KellyL A Harker
May 30, 1991·The New England Journal of Medicine·J Hirsh
Oct 27, 1988·The New England Journal of Medicine·P ThérouxP deGuise
Jan 1, 1981·American Heart Journal·W GanzH J Swan

❮ Previous
Next ❯

Citations

Nov 1, 1993·Cardiovascular Drugs and Therapy·R C Becker
Jan 1, 1995·Journal of Thrombosis and Thrombolysis·J A Purvis
Jan 1, 1995·Journal of Thrombosis and Thrombolysis·C P Cannon, R Tracy
Jan 16, 2007·Journal of Thrombosis and Thrombolysis·Jonathan D RichChristopher P Cannon
Oct 1, 1993·Journal of the American College of Cardiology·E DeutschR W Colman
Jan 23, 2003·The Annals of Thoracic Surgery·Zev DavisAraldo Valgiusti
Feb 9, 2002·Clinical Therapeutics·Timothy D Gladwell
Apr 1, 1997·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·M A YenariG K Steinberg
Mar 9, 1995·Journal of Interventional Cardiology·C P CannonE M Antman
Apr 18, 1994·Annals of the New York Academy of Sciences·D Fitzgerald
Oct 1, 1995·British Heart Journal·M L Simoons, J W Deckers
Jan 1, 1994·Annual Review of Medicine·P H Johnson
Apr 10, 2002·Pharmacotherapy·Simon de Denus, Sarah A Spinler
Jul 1, 1994·Journal of Cardiac Surgery·N I KondoS Z Goldhaber
May 28, 2005·Anaesthesia·P C A KamC L Thong
Sep 27, 2008·Pediatric Blood & Cancer·Sobharani RayapudiMichael D Tarantino
Nov 22, 2001·American Heart Journal·E M Antman, E Braunwald
Nov 4, 2000·Expert Opinion on Investigational Drugs·R Scatena
Jun 5, 2003·Expert Opinion on Investigational Drugs·Amar M Salam
May 31, 2002·Expert Opinion on Pharmacotherapy·Harvey D White, Derek P Chew
Jul 15, 2005·Expert Opinion on Pharmacotherapy·Theodore E Warkentin, Andreas Koster
Apr 23, 2004·Journal of Vascular and Interventional Radiology : JVIR·J J Connors
Jan 11, 2005·Hematology/oncology Clinics of North America·Eugene P FrenkelBarbara B Haley
May 21, 2004·Expert Review of Cardiovascular Therapy·Eric R Bates
Oct 22, 2004·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Mahmut TobuJawed Fareed
Sep 1, 1994·Circulation·J Lefkovits, E J Topol
Nov 16, 1999·Circulation·D F KongR M Califf
Dec 5, 2018·Expert Opinion on Pharmacotherapy·Marc LaineLaurent Bonello
Mar 3, 2012·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Thaddaus R HellwigMichael P Gulseth
Jun 12, 2004·Blood·Jack HirshJeffrey I Weitz
Apr 16, 2003·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·Fredrik SchersténLars Grip
May 23, 2002·The Annals of Pharmacotherapy·Tina M Sciulli, Vincent F Mauro
Apr 27, 2002·Heart Disease·J J Nawarskas, J R Anderson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.